Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
Rhea-AI Summary
Zevra Therapeutics (NASDAQ:ZVRA), a commercial-stage rare disease therapy company, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 11:30 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 10:00 a.m. ET.
Management will be available for one-on-one meetings with registered attendees, and live webcasts of the presentations will be accessible through the Investor Relations section of Zevra's website.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
In the Aug 26 session, ZVRA gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate in the following September events:
- Cantor Global Healthcare Conference on Wednesday, Sept. 3, 2025, at 11:30 a.m. ET.
- H.C. Wainwright 27th Annual Global Investment Conference on Monday, Sept. 8, 2025, at 10:00 a.m. ET.
Additionally, management will be available for one-on-one meetings with registered conference attendees. The live webcasts will be accessible via “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company combining science, data and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed on August 12, 2025, and Zevra’s other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
